There were no treatment-related deaths and no cardiac function abnormalities.\n\nConclusions:

This study indicates that FEC followed by weekly paclitaxel with bevacizumab is an active neoadjuvant regimen for locally advanced breast cancer, with no major safety concerns. Clinical trial registration: NCT00559845. (C) 2013 Elsevier Ltd. All rights reserved.”
“OBJECTIVES\n\nTo examine the association between mobility levels of older hospitalized adults and functional outcomes.\n\nDESIGN\n\nProspective cohort study.\n\nSETTING\n\nA 900-bed teaching hospital in Israel.\n\nPARTICIPANTS\n\nFive hundred twenty-five older (>= 70) acute medical patients hospitalized for a nondisabling condition.\n\nMEASUREMENTS\n\nIn-hospital mobility was assessed using a previously Selleckchem GS-7977 validated scale. The main outcomes were decline selleck from premorbid baseline functional status at discharge (activities of daily living (ADLs)) and at 1-month follow-up (ADLs and instrumental ADLs (IADLs)). Hospital mobility levels and functional outcomes were assessed according to prehospitalization functional

trajectories. Logistic regressions were modeled for each outcome, controlling for functional status, morbidity, and demographic characteristics.\n\nRESULTS\n\nForty-six percent of participants had declined in ADLs at discharge and 49% at follow-up; 57% had declined in IADLs at follow-up. Mobility during hospitalization was twice as high in participants with no preadmission functional decline. Low versus high in-hospital mobility LCL161 research buy was associated with worse basic functional status at discharge (adjusted odds ratio (AOR)=18.03, 95% confidence interval (CI)=7.68-42.28) and at follow-up (AOR=4.72, 95% CI=1.98-11.28) and worse IADLs at follow-up (AOR=2.00, 95% CI=1.05-3.78). The association with poorer

discharge functional outcomes was present in participants with preadmission functional decline (AOR for low vs high mobility=15.26, 95% CI=4.80-48.42) and in those who were functionally stable (AOR for low vs high mobility=10.12, 95% CI=2.28-44.92).\n\nCONCLUSION\n\nIn-hospital mobility is an important modifiable factor related to functional decline in older adults in immediate and short-term (1-month follow-up) functional outcomes.”
“The rhizome of ginger (Zingiber officinale Roscoe) has been reputed to have many curative properties in traditional medicine, and recent publications have also shown that many agents in ginger possess anticancer properties. Here we show that the ethyl acetate fraction of ginger extract can inhibit the expression of the two prominent molecular targets of cancer, the human telomerase reverse transcriptase (hTERT) and c-Myc, in A549 lung cancer cells in a time-and concentration-dependent manner.

No related posts.